Fuentes

Todo lo que publicamos sobre cannabis, en el sitio y en Instagram, sale de tres investigaciones propias sobre salud mental, cognición y salud física, que se apoyan en literatura revisada por pares. Aquí está la bibliografía completa, ordenada por tema. Priorizamos revisiones sistemáticas y metaanálisis; los estudios individuales se usan cuando aportan un diseño experimental o un seguimiento largo.

• Salud mental, trastorno por consumo y abstinencia (31)
• Memoria, motivación, creatividad y sueño (36)
• Salud física, seguridad, embarazo y uso medicinal (24)
• Organismos oficiales y tests (8)

Salud mental, trastorno por consumo y abstinencia

1. Bahji, A., Stephenson, C., Tyo, R., Hawken, E. R., & Seitz, D. P. (2020). Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: A systematic review and meta-analysis. JAMA Network Open, 3(4), e202370. PMID: 32271390. DOI: 10.1001/jamanetworkopen.2020.2370.

   Ver en PubMed

2. Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021). Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 7(1), 16. PMID: 33627670. DOI: 10.1038/s41572-021-00247-4.

   Ver en PubMed

3. Connor, J. P., Stjepanović, D., Budney, A. J., Le Foll, B., & Hall, W. D. (2022). Clinical management of cannabis withdrawal. Addiction, 117(7), 2075–2095. PMID: 34791767. DOI: 10.1111/add.15743.

   Ver en PubMed

4. Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe: The EU-GEI multicentre case-control study. The Lancet Psychiatry, 6(5), 427–436. PMID: 30902669. DOI: 10.1016/S2215-0366(19)30048-3.

   Ver en PubMed

5. Englund, A., Oliver, D., Chesney, E., Chester, L., Wilson, J., Sovi, S., De Micheli, A., Hodsoll, J., Fusar-Poli, P., Strang, J., Murray, R. M., Freeman, T. P., & McGuire, P. (2023). Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology, 48(6), 869–876. PMID: 36380220. DOI: 10.1038/s41386-022-01478-z.

   Ver en PubMed

6. Fontanella, C. A., Steelesmith, D. L., Brock, G., Bridge, J. A., Campo, J. V., & Fristad, M. A. (2021). Association of cannabis use with self-harm and mortality risk among youths with mood disorders. JAMA Pediatrics. DOI: 10.1001/jamapediatrics.2020.5494.

   Ver fuente

7. Freeman, D., Dunn, G., Murray, R. M., Evans, N., Lister, R., Antley, A., et al. (2015). How cannabis causes paranoia: Using the intravenous administration of Δ9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophrenia Bulletin, 41(2), 391–399. PMID: 25031222. DOI: 10.1093/schbul/sbu098.

   Ver en PubMed

8. Gobbi, G., Atkin, T., Zytynski, T., Wang, S., Askari, S., Boruff, J., et al. (2019). Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta-analysis. JAMA Psychiatry, 76(4), 426–434. PMID: 30758486. DOI: 10.1001/jamapsychiatry.2018.4500.

   Ver en PubMed

9. Hall, W., Yimer, T. M., Thorne, R. L., Hoch, E., Burke, C., Gridley, A., Hurd, Y. L., Wilson, J., Leung, J., & Freeman, T. P. (2026). Relationships between cannabis use and mental disorders: Assessing the coherence of evidence from studies with different methodologies. The Lancet Psychiatry, 13(7), 604–614. PMID: 42309106. DOI: 10.1016/S2215-0366(26)00086-6.

   Ver en PubMed

10. Hirvonen, J., Goodwin, R. S., Li, C.-T., Terry, G. E., Zoghbi, S. S., Morse, C., et al. (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry, 17(6), 642–649. PMID: 21747398. DOI: 10.1038/mp.2011.82.

    Ver en PubMed

11. Leung, J., Chan, G. C. K., Hides, L., & Hall, W. D. (2020). What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addictive Behaviors, 109, 106479. PMID: 32485547. DOI: 10.1016/j.addbeh.2020.106479.

    Ver en PubMed

12. Lowe, D. J. E., Sorkhou, M., & George, T. P. (2024). Cannabis use in adolescents and anxiety symptoms and disorders: A systematic review and meta-analysis. The American Journal of Drug and Alcohol Abuse, 50(2), 150–161. PMID: 38285048. DOI: 10.1080/00952990.2023.2299922.

    Ver en PubMed

13. Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269. PMID: 26884547.

    Ver en PubMed

14. Petrilli, K., Ofori, S., Hines, L., Taylor, G., Adams, S., & Freeman, T. P. (2022). Association of cannabis potency with mental ill health and addiction: A systematic review. PMID: 35901795.

    Ver en PubMed

15. Poyatos-Pedrosa, C., et al. (2024). Cannabis and anhedonia: A systematic review. Psychiatry Research, 339, 116041. PMID: 38959579. DOI: 10.1016/j.psychres.2024.116041.

    Ver en PubMed

16. Schoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., et al. (2016). Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. The Lancet Psychiatry, 3(3), 215–225. PMID: 26777297. DOI: 10.1016/S2215-0366(15)00363-6.

    Ver en PubMed

17. Schoeler, T., Petros, N., Di Forti, M., Klamerus, E., Foglia, E., Ajnakina, O., et al. (2016). Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: An observational study. The Lancet Psychiatry, 3(10), 947–953. DOI: 10.1016/S2215-0366(16)30188-2.

    Ver en PubMed

18. Schuster, R. M., Gilman, J., Schoenfeld, D., Evenden, J., Hareli, M., Ulysse, C., Nip, E., Hanly, A., Zhang, H., & Evins, A. E. (2018). One month of cannabis abstinence in adolescents and young adults is associated with improved memory. The Journal of Clinical Psychiatry, 79(6), 17m11977. PMID: 30408351. DOI: 10.4088/JCP.17m11977.

    Ver en PubMed

19. Scott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., & Gur, R. C. (2018). Association of cannabis with cognitive functioning in adolescents and young adults: A systematic review and meta-analysis. JAMA Psychiatry, 75(6), 585–595. DOI: 10.1001/jamapsychiatry.2018.0335.

    Ver fuente

20. Solmi, M., et al. (2023). Balancing risks and benefits of cannabis use: Umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ, 382, e072348. PMID: 37648266. DOI: 10.1136/bmj-2022-072348.

    Ver en PubMed

21. Sorkhou, M., Bedder, R. H. S., & George, T. P. (2024). Cannabis use and mood disorders: A systematic review. Frontiers in Public Health, 12, 1346207. PMID: 38655516. DOI: 10.3389/fpubh.2024.1346207.

    Ver en PubMed

22. Starzer, M. S. K., Nordentoft, M., & Hjorthøj, C. (2018). Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. American Journal of Psychiatry. PMID: 29179576.

    Ver en PubMed

23. Tourjman, S. V., et al. (2023). A systematic review and recommendations of cannabis use in bipolar disorder and major depressive disorder. Canadian Journal of Psychiatry. PMID: 35711159.

    Ver en PubMed

24. Xue, S., Husain, M. I., Zhao, H., & Ravindran, A. V. (2021). Cannabis use and prospective long-term association with anxiety: A systematic review and meta-analysis of longitudinal studies. Canadian Journal of Psychiatry, 66(2), 126–138. PMID: 32909828. DOI: 10.1177/0706743720952251.

    Ver en PubMed

25. Young-Wolff, K. C., Cortez, C. A., Alexeeff, S. E., Silver, L. D., Pacula, R. L., Slama, N. E., et al. (2026). Adolescent cannabis use and risk of psychotic, bipolar, depressive, and anxiety disorders. JAMA Health Forum, 7(2), e256839. PMID: 41719031. DOI: 10.1001/jamahealthforum.2025.6839.

    Ver en PubMed

26. Wilson, J., et al. (2026). The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: Systematic review and meta-analysis of randomised controlled trials. The Lancet Psychiatry, 13(4), 304–315. PMID: 41856154. DOI: 10.1016/S2215-0366(26)00015-5.

    Ver en PubMed

27. Wilson, J., et al. (2026). Correction to the above systematic review. The Lancet Psychiatry. PMID: 42302809. DOI: 10.1016/S2215-0366(26)00176-8.

    Ver en PubMed

28. National Institute on Drug Abuse. (2024). Cannabis (Marijuana) DrugFacts / cannabis information pages. NIH/NIDA.

    Ver fuente

29. Substance Abuse and Mental Health Services Administration. (2024). National Survey on Drug Use and Health: methodological definitions and substance use disorder measures. SAMHSA.

    Ver fuente

30. European Union Drugs Agency. (2026). European Drug Report 2026: Cannabis. EUDA.

    Ver fuente

31. World Health Organization. (2025). Schizophrenia. WHO, actualización de 6 de octubre de 2025; incluye el consumo intenso de cannabis entre factores asociados a mayor riesgo en un marco gene-ambiente.

    Ver fuente

Memoria, motivación, creatividad y sueño

1. Althoff, M. D., Kinney, G. L., Aloia, M. S., Sempio, C., Klawitter, J., & Bowler, R. P. (2024). The impact of cannabis use proximal to sleep and cannabinoid metabolites on sleep architecture. Journal of Clinical Sleep Medicine, 20(10), 1615–1625. doi: 10.5664/jcsm.11212.

   Ver en PubMed

2. AminiLari, M., Wang, L., Neumark, S., et al. (2022). Medical cannabis and cannabinoids for impaired sleep: A systematic review and meta-analysis of randomized clinical trials. Sleep, 45, zsab234. doi: 10.1093/sleep/zsab234.

   Ver en PubMed

3. Bloomfield, M. A. P., Ashok, A. H., Volkow, N. D., & Howes, O. D. (2016). The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature, Molecular Psychiatry-related review literature. [Artículo de revisión indexado y disponible en PubMed Central].

   Ver en PubMed Central

4. Burke, C. O., et al. (2024). Residual and enduring effects of cannabis use on cognitive function: A systematic review. [Artículo revisado por pares; publicación electrónica 2024].

   Ver en PubMed Central

5. Chan, O., et al. (2024). Cannabis use during adolescence and young adulthood and academic achievement: A systematic review and meta-analysis. JAMA Pediatrics. PMID: 39374005.

   Ver en PubMed

6. Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2022). Clinical management of cannabis withdrawal. Addiction. PMID: 34791767.

   Ver en PubMed

7. Englund, A., et al. (2023). Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology.

   Ver fuente

8. Figueiredo, P. R., et al. (2020). Neurocognitive consequences of chronic cannabis use: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 108, 358–369. PMID: 31715191. doi: 10.1016/j.neubiorev.2019.10.014.

   Ver en PubMed

9. Gates, P., Albertella, L., & Copeland, J. (2016). Cannabis withdrawal and sleep: A systematic review of human studies. Substance Abuse. PMID: 25893849.

   Ver en PubMed

10. Gowin, J. L., Ellingson, J. M., Karoly, H. C., Manza, P., Ross, J. M., Sloan, M. E., Tanabe, J. L., & Volkow, N. D. (2025). Brain function outcomes of recent and lifetime cannabis use. JAMA Network Open, 8(1), e2457069. doi: 10.1001/jamanetworkopen.2024.57069.

    Ver fuente

11. Gowin, J. L., et al. (2026). Effects of legal-market cannabis and alcohol on verbal learning and memory. Psychopharmacology. PMID: 40996525.

    Ver en PubMed

12. Heng, Y. T., Barnes, C. M., & Yam, K. C. (2023). Cannabis use does not increase actual creativity but biases evaluations of creativity. Journal of Applied Psychology, 108(4), 635–646. PMID: 35901408. doi: 10.1037/apl0000599.

    Ver en PubMed

13. Hindley, G., et al. (2020). Psychiatric symptoms caused by cannabis constituents: A systematic review and meta-analysis. The Lancet Psychiatry. PMID: 32197092.

    Ver en PubMed

14. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025). Cannabis, cannabinoids and health: A review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience, 275(2), 281–292. doi: 10.1007/s00406-024-01880-2. PMID: 39299947.

    Ver en PubMed

15. Kowal, M. A., Hazekamp, A., Colzato, L. S., van Steenbergen, H., & Hommel, B. (2015). Cannabis and creativity: Highly potent cannabis impairs divergent thinking in regular cannabis users. Psychopharmacology. doi: 10.1007/s00213-014-3749-1.

    Ver en PubMed

16. Lawn, W., et al. (2023). The acute effects of cannabis with and without cannabidiol in adults and adolescents: Randomised, double-blind, placebo-controlled, crossover experiment. [Artículo revisado por pares].

    Ver en PubMed

17. Mao, F., Hoepel, S. J. W., Shahisavandi, M., Luik, A. I., & El Marroun, H. (2025). Recreational cannabis use and sleep in the general population: A systematic review and meta-analysis. Sleep Medicine Reviews, 84, 102189. doi: 10.1016/j.smrv.2025.102189. PMID: 41187699.

    Ver en PubMed

18. McCartney, D., Arkell, T. R., Irwin, C., & McGregor, I. S. (2021). Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. Neuroscience & Biobehavioral Reviews, 126, 175–193. doi: 10.1016/j.neubiorev.2021.01.003. PMID: 33497784.

    Ver en PubMed

19. McCartney, D., et al. (2023). The “next day” effects of cannabis use: A systematic review. Cannabis and Cannabinoid Research. doi: 10.1089/can.2022.0185. PMID: 36475998.

    Ver en PubMed

20. Pacheco-Colón, I., Limia, J. M., & Gonzalez, R. (2018). Non-acute effects of cannabis use on motivation and reward sensitivity in humans: A systematic review. Psychology of Addictive Behaviors, 32, 497–507.

    Ver en PubMed Central

21. Pilon, F., Dumais, A., Giguère, C.-É., & Potvin, S. (2025). The effects of cannabis use disorder on cognitive functions: A meta-analysis. Addictive Behaviors. PMID: 40675034.

    Ver en PubMed

22. Ross, J. M., et al. (2020). Investigating the causal effect of cannabis use on cognitive function with a quasi-experimental co-twin design. Drug and Alcohol Dependence, 206, 107712. PMID: 31753729.

    Ver en PubMed

23. Schreiner, A. M., & Dunn, M. E. (2012). Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. Experimental and Clinical Psychopharmacology, 20, 420–429. doi: 10.1037/a0029117.

    Ver fuente

24. Scott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., & Gur, R. C. (2018). Association of cannabis with cognitive functioning in adolescents and young adults: A systematic review and meta-analysis. JAMA Psychiatry, 75(6), 585–595. doi: 10.1001/jamapsychiatry.2018.0335. PMID: 29710074.

    Ver en PubMed

25. Skumlien, M., et al. (2022). Anhedonia, apathy, pleasure, and effort-based decision-making in adult and adolescent cannabis users and controls. [CannTeen study; artículo revisado por pares].

    Ver en PubMed Central

26. Skumlien, M., Langley, C., & Sahakian, B. J. (2024). Is cannabis use associated with motivation? A review of recent acute and non-acute studies. Current Behavioral Neuroscience Reports, 11, 33–43. doi: 10.1007/s40473-023-00268-1.

    Ver fuente

27. Stella, N. (2023). THC and CBD: Similarities and differences between siblings. [Revisión farmacológica revisada por pares, PubMed Central].

    Ver en PubMed Central

28. Suraev, A., et al. (2020). Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. [Revisión sistemática].

    Ver fuente

29. Suraev, A., et al. (2025/2026). Acute effects of oral cannabinoids on sleep and high-density EEG in insomnia: A pilot randomised controlled trial. Journal of Sleep Research, 35(1), e70124. doi: 10.1111/jsr.70124.

    Ver en PubMed Central

30. Velzeboer, R., Malas, A., Wei, S., Berger, R., Parmar, V., & Lai, W. W. K. (2025). Cannabis and sleep architecture: A systematic review and meta-analysis. Sleep Medicine Reviews, 84, 102164. PMID: 40967124. doi: 10.1016/j.smrv.2025.102164.

    Ver en PubMed

31. Velzeboer, R., Wei, S., & Lai, W. W. K. (2025). Chronic cannabis use and sleep architecture: A cross-sectional analysis of polysomnography outcomes in a sleep-clinic cohort. Sleep. doi: 10.1093/sleep/zsaf396.

    Ver fuente

32. Xu, H., et al. (2023). Molecular brain differences and cannabis involvement: A systematic review of positron emission tomography studies. [Revisión sistemática PET].

    Ver fuente

33. Centers for Disease Control and Prevention. (2026, versión consultada). Cannabis and public health: About cannabis.

    Ver fuente

34. European Union Drugs Agency. (2025–2026, versiones consultadas). Cannabis: European drug market / drug profile / production and retail developments.

    Ver fuente

35. Health Canada. (2025–2026). Health effects of cannabis; cannabis product composition and labelling guidance.

    Ver fuente

36. National Center for Complementary and Integrative Health. (2023). When taken orally, Δ9-tetrahydrocannabinol with cannabidiol can result in stronger drug effects than Δ9-tetrahydrocannabinol alone.

    Ver fuente

Salud física, seguridad, embarazo y uso medicinal

1. American College of Obstetricians and Gynecologists. (2025). Cannabis use during pregnancy and lactation: ACOG Clinical Consensus No. 10. Obstetrics & Gynecology. DOI: 10.1097/AOG.0000000000006053.

   Ver fuente

2. American Society of Regional Anesthesia and Pain Medicine. (2023). ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Regional Anesthesia & Pain Medicine.

   Ver fuente

3. American Society for Reproductive Medicine. (2023). Tobacco or marijuana use and infertility: A committee opinion. Fertility and Sterility.

   Ver fuente

4. Camilleri, M. (2023). Cannabinoids and the gastrointestinal tract. Clinical Gastroenterology and Hepatology.

   Ver en PubMed Central

5. Centers for Disease Control and Prevention. (2024). Cannabis and poisoning. Organismo oficial; sin DOI.

   Ver fuente

6. Centers for Disease Control and Prevention. (2024). Cannabis and heart health. Organismo oficial; sin DOI.

   Ver fuente

7. European Union Drugs Agency. (2025). European Drug Report: New psychoactive substances and new cannabinoids. Organismo oficial; sin DOI.

   Ver fuente

8. European Union Drugs Agency. (2026). New psychoactive substances: Market developments and semisynthetic cannabinoids. Organismo oficial; sin DOI.

   Ver fuente

9. Food and Drug Administration. (2024–2026). FDA regulation of cannabis and cannabis-derived products, including cannabidiol. Organismo oficial; sin DOI.

   Ver fuente

10. Groening, J. M., et al. (2024). An umbrella review of systematic reviews and meta-analyses on the health effects of cannabis use. Revisión paraguas. PMID: 38096722.

    Ver en PubMed

11. Health Canada. (2024). Cannabis poisonings in children. Organismo oficial; sin DOI.

    Ver fuente

12. Hoch, E., et al. (2025). Cannabis, cannabinoids and health: A review of evidence on risks and medical benefits. PMID: 39299947.

    Ver en PubMed

13. Jeffers, A. M., et al. (2024). Association of cannabis use with cardiovascular outcomes among US adults. Journal of the American Heart Association. DOI: 10.1161/JAHA.123.030178. PMID: 38415581.

    Ver en PubMed

14. Lo, J. O., et al. (2024). Cannabis use in pregnancy and neonatal outcomes: A systematic review and meta-analysis. Cannabis and Cannabinoid Research. DOI: 10.1089/can.2022.0262. PMID: 36730710.

    Ver en PubMed

15. Lo, J. O., et al. (2025). Prenatal cannabis use and neonatal outcomes: An updated systematic review and meta-analysis. JAMA Pediatrics. PMID: 40323610.

    Ver en PubMed

16. Page, R. L., et al. (2020). Medical marijuana, recreational cannabis, and cardiovascular health: A scientific statement from the American Heart Association. Circulation.

    Ver fuente

17. Simmons, S. M., et al. (2022). The effects of cannabis and alcohol on driving performance and driver behaviour: A systematic review and meta-analysis. Addiction. DOI: 10.1111/add.15770. PMID: 35083810.

    Ver en PubMed

18. Solmi, M., et al. (2023). Balancing risks and benefits of cannabis use: Umbrella review of meta-analyses of randomised controlled trials and observational studies. PMID: 37648266.

    Ver en PubMed

19. Sorensen, C. J., DeSanto, K., Borgelt, L., Phillips, K. T., & Monte, A. A. (2017). Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment—A systematic review. Journal of Medical Toxicology, 13, 71–87. PMID: 28000146.

    Ver en PubMed

20. Storck, W., et al. (2025). Cardiovascular risk associated with the use of cannabis and cannabinoids: A systematic review and meta-analysis. Heart. PMID: 40527600.

    Ver en PubMed

21. Swartz, J. A., & Franceschini, D. (2025). Cannabinoid hyperemesis syndrome, 2016 to 2022. JAMA Network Open, 8(11), e2545310. DOI: 10.1001/jamanetworkopen.2025.45310.

    Ver fuente

22. Wang, L., Hong, P. J., May, C., et al. (2021). Medical cannabis or cannabinoids for chronic non-cancer and cancer-related pain: A systematic review and meta-analysis of randomised clinical trials. BMJ, 374, n1034. DOI: 10.1136/bmj.n1034. PMID: 34497047.

    Ver en PubMed

23. Wymore, E. M., et al. (2021). Persistence of Δ-9-tetrahydrocannabinol in human breast milk. JAMA Pediatrics.

    Ver fuente

24. Young-Wolff, K. C., et al. (2024). Prenatal cannabis use and maternal pregnancy outcomes. JAMA Internal Medicine.

    Ver fuente

Organismos oficiales y tests

1. NIDA, Cannabis (Marijuana).

   Ver fuente

2. CDC, Health Effects of Cannabis.

   Ver fuente

3. SENDA, Cannabis.

   Ver fuente

4. SENDA, sitio institucional.

   Ver fuente

5. Minsal, Salud Responde.

   Ver fuente

6. OMS, ASSIST.

   Ver fuente

7. CAST, propiedades psicométricas.

   Ver en PubMed

8. CUDIT-R, artículo original.

   Ver en PubMed

Ver también: metodología y política editorial.